KRAS and adenocarcinoma: In adenocarcinoma, this analysis suggested that 10.6% (50.3% if including KRAS) of cases could be eligible for emerging targeted treatments, beyond the 15.3% of cases eligible for standard EGFR or ALK targeted therapy (Figure 4D).